A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorImperial College London

About this trial

Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease.

Who can take part?

Adults aged 18 or older who:

Have liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary sclerosing cholangitis, or Have tummy symptoms but a normal liver scan. What's involved?

Participants will:

Give a breath sample after fasting for 6 hours. Answer a few health questions. Allow access to relevant medical records. The appointment lasts about 1 hour at an NHS hospital. Benefits \& Risks

This research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants.

There are no risks, as breath sampling is completely non-invasive and safe. Where is the study happening? Led by Imperial College London, running in NHS hospitals across the UK.

Who is funding the study? The study is funded by Rosetrees and Stoneygate Trust.

Contact Information Email: [email protected] Phone: +44 (0)20 7594 3396

Eligibility criteria

Qualifiers

Males and females

Adult participants ≥ 18 years old

Histologically or radiologically-confirmed* hepatocellular carcinoma or cholangiocarcinoma (participants with liver cancer)

Liver cirrhosis, confirmed on imaging or histology from biopsy (participants with benign liver disorders)

Disqualifiers

Active infection, or receiving immunosuppressive medications, within the preceding eight weeks

History of another cancer within the previous five years

Previous liver resection

Already received chemotherapy, radiotherapy or surgery for their liver cancer

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

750 Participants
are grouped into 3 trial groups

Sponsors and collaborators